AUS
NZ
UK
CA
USA
IND
_02_06_2025_07_05_23_538703.jpg)
_07_03_2026_03_50_21_133108.jpg)
Lumos Diagnostics (ASX:LDX), a pioneer in rapid point-of-care diagnostic solutions, announced FY26 total revenue of US$13.2 million, marking a 6% year-over-year increase, with FebriDx product revenue skyrocketing 875% to US$3.9 million. The company secured pivotal CLIA waiver milestone payments totaling US$5.5 million from its exclusive US distributor PHASE Scientific and the Biomedical Advanced Research and Development Authority (BARDA), enabling access to more than 300,000 healthcare sites across the US. With over 170 healthcare locations in 24 states actively ordering FebriDx and a cash reserve of US$15.4 million, Lumos is advancing its rapid diagnostic platform into mainstream outpatient care settings nationwide.
Key Highlights
- Lumos Diagnostics (ASX:LDX) specializes in rapid point-of-care diagnostics for acute respiratory infections and fetal fibronectin assessment.
- FY26 total revenue reached US$13.2 million, up 6% year-on-year, with FebriDx product revenue surging 875% to US$3.9 million.
- US FDA granted CLIA waiver on 27 March 2026, triggering milestone payments of US$5.0 million from PHASE Scientific and US$0.5 million from BARDA, plus an additional US$0.7 million for completing Milestone #7 in the BARDA-funded pediatric study.
- US commercialization accelerating with 170+ healthcare locations across 24 states actively ordering FebriDx , supported by partnerships with PHASE Scientific, PRO-spectus, AcuityMD, MTMC, and CG Life.
- Q4 FY26 operating cash inflow was US$2.7 million; cash balance stood at US$15.4 million as of 30 June 2026.
- Hologic fetal fibronectin (fFN) project extended to June 2028 with ongoing Phases 2 and 3, affecting Services revenue amortization.
FebriDx CLIA Waiver Unlocks 15-Fold US Market Expansion Opportunity
The US FDA’s Clinical Laboratory Improvement Amendments (CLIA) waiver granted to FebriDx on 27 March 2026 marks a transformative milestone for Lumos Diagnostics. This waiver expands FebriDx addressable market approximately 15-fold, extending availability from limited CLIA-certified labs to over 300,000 healthcare locations nationwide. This regulatory breakthrough significantly broadens access to more than 80 million US patients annually with acute respiratory infections and opens a market opportunity exceeding US$1 billion.
The CLIA waiver permits FebriDx use across a broad spectrum of healthcare settings holding a Certificate of Waiver, including primary care offices, urgent care centers, retail health and pharmacy clinics, and community health centers. This regulatory advancement removes a key barrier to widespread commercialization and aligns with Lumos’ strategy to integrate FebriDx into mainstream outpatient workflows. It reflects US health authorities’ confidence that FebriDx can be reliably administered and interpreted outside traditional labs, making it accessible where patients with respiratory infections typically seek care.
Strategic Milestone Payments Totaling US$5.5 Million Received from PHASE Scientific and BARDA
The CLIA waiver achievement triggered milestone payments underscoring its commercial value to Lumos’ partners. PHASE Scientific, the exclusive US distributor, paid US$5.0 million on 14 April 2026 under the US distribution agreement valued at US$317 million over six years, announced 16 July 2025. This substantial upfront payment highlights PHASE Scientific’s confidence in the expanded market potential and commitment to accelerating FebriDx adoption across US healthcare.
Additionally, Lumos received US$0.5 million from BARDA on 7 May 2026 for the CLIA waiver milestone and US$0.7 million for completing Milestone #7 in the BARDA-funded pediatric study after enrolling 250 patients. These payments demonstrate progress in both the US commercial pathway and pediatric clinical development, a crucial segment for acute respiratory infection diagnostics.
FebriDx Revenue Soars 875% Fueled by PHASE Scientific Distribution Partnership
FebriDx product revenue for FY26 reached US$3.9 million, an extraordinary 875% increase from US$0.4 million in FY25. This surge was driven primarily by robust sales orders from PHASE Scientific following the distribution agreement’s execution. The revenue growth reflects PHASE’s ramped ordering and early adoption by US healthcare providers as the market opened to broader distribution.
In Q4 FY26, FebriDx sales dipped compared to Q3 FY26 due to expected seasonal slowdowns and shipment timing, with significant PHASE orders recognized in Q3 (February and March 2026). The seasonal demand pattern is typical of respiratory diagnostics, with higher volumes expected during Northern Hemisphere winter. Despite the quarterly dip, the full-year growth validates the commercial strategy of partnering with an experienced US distributor to scale FebriDx rapidly.
170+ Healthcare Locations Across 24 US States Actively Ordering FebriDx
Lumos’ US commercialization advances through targeted healthcare provider engagement and strategic partnerships accelerating FebriDx adoption. Currently, over 170 healthcare sites in 24 states actively order and use FebriDx , showing broad geographic market penetration beyond initial pilots. This distribution across states and provider types reflects growing awareness and use of rapid respiratory diagnostics across diverse US markets.
Commercial efforts are supported by partnerships with PHASE Scientific (exclusive distributor), PRO-spectus, AcuityMD, MTMC (providing clinical implementation training and support for Tier 1 and 2 customers), and CG Life (strategic marketing partner). The CG Life partnership, selected after a competitive review, is key to building commercial infrastructure to fully realize FebriDx potential in the US outpatient market.
WellStreet Urgent Care Expansion Program Progressing Toward Full Network Rollout
WellStreet Urgent Care confirmed on 14 April 2026 it will expand its FebriDx program from a single Atlanta pilot to 43 additional locations across the Fayetteville District, a second Georgia district, and the Michigan market, completing this phase by mid-June 2026. This expansion validates pilot success and provider confidence in FebriDx clinical and operational fit within urgent care workflows.
The final phase will roll out FebriDx to all 165 WellStreet sites over 3 to 9 months, aiming for maximum site activation by the upcoming US flu season. This staged rollout facilitates training, integration, and performance validation at each stage. Adoption by this multi-state urgent care network is significant, targeting a core market where rapid point-of-care respiratory diagnostics have high clinical value.
Services Revenue Declines Due to Hologic fFN Project Extension to June 2028
Services revenue for FY26 fell 16% to US$8.9 million from US$10.6 million in FY25, mainly due to extension of the Hologic fetal fibronectin (fFN) project timeline. The project’s Phases 2 and 3 are ongoing with additional scope, shifting the estimated completion to June 2028 and reducing intellectual property license fee revenue from US$4.6 million in FY25 to US$1.4 million in FY26.
Excluding IP license fee reductions, project revenue rose US$1.5 million to US$7.5 million in FY26, a 24% year-over-year increase, reflecting progress across customer projects and higher contract research and development activity. In Q4 FY26, 12 customer projects drove 39% growth in contract research and development revenue, indicating sustained momentum despite the Hologic project delay.
FY26 Total Revenue of US$13.2 Million Reflects Shift from ViraDx to CorDx Products
Unaudited FY26 revenue totaled US$13.2 million, up 6% from US$12.4 million in FY25, despite transitioning from Lumos’ proprietary ViraDx influenza test to a third-party CorDx Flu A/B/COVID combo test due to pricing competitiveness. CorDx sales of US$0.2 million did not match prior ViraDx sales, causing a US$1.1 million decline in this product category year-on-year.
Overall Products revenue grew 135% to US$4.3 million, driven almost entirely by FebriDx revenue growth of 875%, offsetting influenza test declines. This demonstrates successful commercialization of FebriDx and validates Lumos’ strategic focus on higher-value rapid diagnostics with broader clinical applications and larger addressable markets.
Q4 FY26 Operating Cash Inflow of US$2.7 Million Supported by Increased Customer Receipts
Lumos reported Q4 FY26 operating cash inflow of US$2.7 million, fueled by higher customer payments. This positive cash flow confirms revenue growth is translating into liquidity, with distributor and customer payment terms supporting financial stability. The company held US$15.4 million in cash as of 30 June 2026, underpinning ongoing commercialization and operational investments for FebriDx growth and contract research projects.
This cash flow milestone reduces reliance on external funding and provides flexibility to invest in strategic initiatives such as the CG Life marketing partnership and MTMC clinical training without immediate capital raises.
FebriDx Regulatory Approvals Now Span Six Markets Including US and EU
FebriDx has secured regulatory registrations across six markets: United States, United Kingdom, European Union, Kuwait, United Arab Emirates, and Australia. These approvals demonstrate successful navigation of diverse regulatory environments and provide optionality for future geographic expansion and revenue diversification. The recent US CLIA waiver is the most commercially significant milestone.
The broad regulatory acceptance underscores FebriDx clinical validation and credibility with international health authorities, supporting Lumos’ potential to expand beyond the US as commercial and distribution capabilities mature.
Contract Research and Development Services Revenue Grows 39% in Q4 FY26 Despite Hologic Delays
Contract research and development services revenue increased 39% in Q4 FY26, even as overall Services revenue declined 10% from the prior quarter due to reduced Hologic IP amortization. This growth reflects strong demand for Lumos’ technical expertise and active engagement in 12 customer projects during the quarter.
The divergence between Services revenue decline and contract research growth highlights the underlying strength and diversification of Lumos’ Services business, reducing dependence on FebriDx and providing multiple revenue streams. The 24% year-over-year growth in project revenue (excluding Hologic IP) confirms successful execution of customer projects and contributes to financial stability alongside FebriDx commercialization.
